Compare SNDR & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNDR | ABVX |
|---|---|---|
| Founded | 1935 | 2013 |
| Country | United States | France |
| Employees | N/A | 69 |
| Industry | Trucking Freight/Courier Services | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.2B |
| IPO Year | 2016 | N/A |
| Metric | SNDR | ABVX |
|---|---|---|
| Price | $35.88 | $96.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 13 |
| Target Price | $27.83 | ★ $131.31 |
| AVG Volume (30 Days) | 1.1M | ★ 2.8M |
| Earning Date | 04-30-2026 | 03-23-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $5,674,300,000.00 | N/A |
| Revenue This Year | $5.11 | $52.14 |
| Revenue Next Year | $6.05 | $4,132.27 |
| P/E Ratio | $301.75 | ★ N/A |
| Revenue Growth | ★ 7.25 | N/A |
| 52 Week Low | $20.11 | $7.41 |
| 52 Week High | $39.27 | $148.83 |
| Indicator | SNDR | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 43.75 |
| Support Level | $26.88 | $87.60 |
| Resistance Level | $39.27 | $98.59 |
| Average True Range (ATR) | 1.26 | 7.37 |
| MACD | -0.42 | -0.07 |
| Stochastic Oscillator | 23.46 | 71.13 |
Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, LTL carriers, railroads, ocean carriers, airlines to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload, Intermodal, Logistics and other. It generates maximum revenue from the Truckload segment.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.